About
Bio
Impact Factor:
0.464 (© 2015 Thomson Reuters, Journal Citation Reports®)
Circulation:
The Publisher does not disclose the circulation.
Aims of the Journal:
Expert Opinion on Orphan Drugs is an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs.
The Editors welcome:
Reviews that focus on rare diseases or orphan drugs, and report on any of the following topics: diagnostics, pharmacogenomics and screening; prevalence and epidemiology (with particular attention to regional variations); drug development; lead generation and discovery; early or late phase clinical trials; regulatory issues; post-marketing safety; treatment outcomes.
Drug Evaluations specifically reviewing the pharmacological properties; clinical potential/clinical efficacy; safety and, if applicable, HE/OR data on a particular orphan drug.
Original Research papers reporting the results of early or late stage clinical investigations or HE/OR data on orphan drugs and studies in the treatment of rare diseases.
Editorials, commentaries and meeting-highlights papers covering topics in rare diseases.
Instructions for Authors / Submission Guidance:
This can be found here
Email
email@cision.one
Website
site@cision.one
Social media
Location
United Kingdom
Frequency
upgrade
Circulation
upgrade
Sectors
Pharmaceuticals
Bio
Impact Factor: 0.464 (© 2015 Thomson Reuters, Journal Citation Reports®) Circulation: The Publisher does not disclose the circulation. Aims of the Journal: Expert Opinion on Orphan Drugs is an international, peer-reviewed journal that covers all aspects of R&D on rare diseases and orphan drugs. The Editors welcome: Reviews that focus on rare diseases or orphan drugs, and report on any of the following topics: diagnostics, pharmacogenomics and screening; prevalence and epidemiology (with particular attention to regional variations); drug development; lead generation and discovery; early or late phase clinical trials; regulatory issues; post-marketing safety; treatment outcomes. Drug Evaluations specifically reviewing the pharmacological properties; clinical potential/clinical efficacy; safety and, if applicable, HE/OR data on a particular orphan drug. Original Research papers reporting the results of early or late stage clinical investigations or HE/OR data on orphan drugs and studies in the treatment of rare diseases. Editorials, commentaries and meeting-highlights papers covering topics in rare diseases. Instructions for Authors / Submission Guidance: This can be found here
Website
Social media
Location
Frequency
Circulation
Sectors
Pharmaceuticals
Most recent articles by Expert Opinion on Orphan Drugs
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Explore outlets similar to Expert Opinion on Orphan Drugs
-
SScience
Founded in 1880, with seed money from Thomas Edison, Science continues to be at the center of the very best in research across the sciences, with articles that consistently rank among the most cited in the world. Science articles are peer-reviewed, and written to appeal to both scientist and layman. Regular issue features include a news and comment section, book reviews, and coverage of scientific meetings and seminars. The News section features late-breaking news and in-depth news analysis. Compass, an opinion section, publishes letters and commentary by scientists on current science issues. The TechSight section focuses on leading edge techniques and technologies. Topics include: bioinformatics, genome sequencing, and protein sequencing. This section is published in the third issue every month. The Research section features original investigative research and reporting. Other departments include NetWatch, This Week in Science, ScienceScope, Random Samples and New Products.
ViewMMedscapeMedscape was created for medical specialists, primary care physicians, and health professionals and offers medical news, clinical trial information, review articles, journal commentary, expert columns, patient education articles and book reviews. It also includes Web-based services for verifying insurance information, Medline and other search engines, as well as a physician directory enabling users to find physicians by practice, location or specialty.
ViewTThe BMJThe BMJ is a leading international peer‑reviewed general medical journal that publishes high‑quality research, clinical reviews, expert analysis, news, opinion, education, evidence‑based guidance and commentary on clinical practice, public health, healthcare policy and related scientific and social issues affecting medicine and health professionals worldwide. It combines rigorous academic research with accessible content aimed at informing and improving healthcare decisions and outcomes globally.
ViewEEndpoints NewsEndpoints News covers Biopharmaceutical industry. Offers data-driven news and analysis for industry professionals covering research and development. Content is a combination of originally produced and curated from around the web and is available in real-time and via a daily newsletter. This site is available via RSS (Really Simple Syndication).
ViewTThe Pharmaceutical JournalThe Pharmaceutical Journal is the official professional journal of the Royal Pharmaceutical Society that provides authoritative news, analysis, and insight on pharmacy practice, pharmaceutical science, medicines use, healthcare policy, and professional developments affecting pharmacists, pharmaceutical scientists, policy makers and other healthcare professionals. Its content includes current news, expert commentary, features, opinion pieces, learning articles, and career advice, with a focus on advancing understanding of pharmacy practice and the pharmaceutical sciences globally.
ViewUse CisionOne to find more relevant outletsContact Expert Opinion on Orphan Drugs and get access to over 850K accurate, up-to-date media profiles.
Discover the stories that impact your brand. In realtime.
CisionOne delivers relevant news, trends and conversations that matter to your brand with the world’s most comprehensive media monitoring service across Print, Online, TV, Radio, Social, Magazines, Podcasts and more.